FibroBiologics, Inc.
For the period ended Sep 30, 2025. Filed Oct 31, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 31, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
The following sets forth information regarding all unregistered securities we sold during the nine months ended September 30, 2025. Unless stated otherwise, the sales of the securities listed below were deemed to be exempt from registration pursuant to Section 4(a)(2) of the Securities Act, as transactions by an issuer not involving a public offering.
On January 7, 2025, we satisfied the commitment fee due under the SEPA with YA II PN, LTD., or the Investor, by issuing 118,991 shares of our Common Stock to the Investor at a $2.1010 price per share.
Below is a summary of conversions during the nine months ended September 30, 2025 by the Investor of short-term convertible notes issued to the Investor under the SEPA:
| Date | Tranche | Principal Amount | Shares Issued | Price Per Share |
|---|---|---|---|---|
| January 23, 2025 | Second Note | $900,000 | 552,113 | $1.6301 |
| January 27, 2025 | Second Note | $500,000 | 317,238 | $1.5761 |
| January 29, 2025 | Second Note | $500,000 | 334,336 | $1.4955 |
| February 7, 2025 | Second Note | $1,100,000 | 732,941 | $1.5008 |
| February 21, 2025 | Second Note | $250,000 | 232,169 | $1.0768 |
| March 4, 2025 | Second Note | $350,000 | 361,794 | $0.9674 |
| April 11, 2025 | Second Note | $200,000 | 263,643 | $0.7586 |
| April 15, 2025 | Second Note | $200,000 | 263,643 | $0.7586 |
| May 15, 2025 | Second Note | $300,000 | 388,450 | $0.7723 |
| June 2, 2025 | Second Note | $100,000 | 147,579 | $0.6776 |
| June 3, 2025 | Second Note | $300,000 | 442,739 | $0.6776 |
| June 20, 2025 | Second Note | $100,000 | 144,216 | $0.6934 |
| June 24, 2025 | Second Note | $200,000 | 295,377 | $0.6771 |
| June 26, 2026 | Third Note | $300,000 | 443,066 | $0.6771 |
| June 27, 2025 | Third Note | $500,000 | 738,443 | $0.6771 |
| July 15, 2025 | Third Note | $300,000 | 533,428 | $0.5624 |
| July 28, 2025 | Third Note | $300,000 | 493,258 | $0.6082 |
| August 1, 2025 | Third Note | $600,000 | 1,035,911 | $0.5792 |
| August 18, 2025 | Third Note | $300,000 | 571,537 | $0.5249 |
| August 25, 2025 | Third Note | $300,000 | 544,959 | $0.5505 |
| September 9, 2025 | Third Note | $300,000 | 566,572 | $0.5295 |
| September 16, 2025 | Third Note | $300,000 | 597,133 | $0.5024 |
| September 25, 2025 | Third Note | $400,000 | 815,660 | $0.4904 |
| September 30, 2025 | Third Note | $1,100,000 | 2,243,065 | $0.4904 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.